Inspiration Healthcare Group plc
("Inspiration Healthcare", the "Company" or the "Group")
Appointment of Chief Financial Officer
and
Grant of Options
Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company pioneering best-in class, specialist neonatal intensive care medical devices, announces the appointment of Alan Olby ACA as Chief Financial Officer and a Director of the Company, effective immediately.
Alan is an experienced and commercially focused healthcare CFO, with extensive international and operational experience within fast-growing listed and private healthcare companies. He spent 16 years at Sinclair Pharma, of which 12 years were as CFO and a member of the executive leadership team and he was instrumental in transforming the company into a fast growth global aesthetics business, which was sold to Huadong Medicine Co Ltd for £165 million in 2018.
During his tenure he oversaw several successful capital raises, and a number of strategic M&A transactions, including the disposal of the non-core business to Alliance Pharma for £132 million in 2015. Prior to Sinclair Pharma, Alan was Group Financial Controller of Xenova Group plc and KS Biomedix plc.
Neil Campbell, Chief Executive Officer of Inspiration Healthcare said: "We are delighted to have someone of Alan's calibre join Inspiration Healthcare. His track record of building and growing a commercial healthcare business and his experience of capital markets will be invaluable as we continue to execute our strategy and build a world leading innovative medical technology company focused on neonatal intensive care."
Alan Olby, incoming Chief Financial Officer commented: "I am delighted to be joining Inspiration Healthcare at this exciting stage in the Group's development. The Group's world class design and manufacturing expertise enables it to provide a broad range of specialist, innovative products that address the critical needs within the global neonatal market and I look forward to working to accelerate the Group's growth strategy."
In accordance with Schedule 2 (g) of the AIM Rules for Companies, Alan Musgrave Olby (aged 52 years) holds/has held the following directorships/partnerships in the last five years:
| Current directorships/partnerships | Previous directorships/partnerships (last five years) |
| None | Acorus Therapeutics Limited |
| | Aqtis Medical BV |
| | Cocoon Medical Italy SRL Cocoon Medical Colombia SAS Cocoon Medical Hong Kong Limited Cocoon Medical International EOOD Cocoon Medical USA LLC |
| | High Technology Products SL |
| | IS Pharma Limited |
| | IS Pharmaceuticals Limited Sinclair Aesthetics De Mexico S.A. De C.V. Sinclair Chile SPA Sinclair Korea Limited |
| | Silhouette Lift SL |
| | Sinclair France SAS |
| | Sinclair Holding BV |
| | Sinclair Holdings Iberia SL |
| | Sinclair Netherlands IP BV |
| | Sinclair Pharma GmbH |
| | Sinclair Pharma Holdings Limited |
| | Sinclair Pharma Limited |
| | Sinclair Pharma Man Co Limited |
| | Sinclair Pharma Management Limited |
| | Sinclair Pharmaceutical Espana SL. |
| | Sinclair Pharmaceuticals (Asia Pacific) Pte. Ltd |
| | Sinclair Pharmaceuticals Limited |
| | Sinclair Pharmaceuticals Limited Singapore Branch |
| | Sinclair Pharmaceuticals Limited Sp. z o.o. Sinclair Lifesciences India Private Ltd |
| | Speciality European Pharma International AG Viora Inc. |
| | Viora Canada Ltd |
| | Viora Ltd |
Alan Olby resigned as a director of Speciality European Pharma International AG in the 12 months prior to the company going into liquidation on 29 November 2018.
Other than the award of share options, as noted below, Alan Olby has no existing interest in the ordinary shares of the Company.
There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.
Grant of Options
Alan Olby has been granted a total of 222,222 nil cost options over ordinary shares of 10 pence each in the capital of the Company ("Options") under the Inspiration Healthcare Group Long Term Incentive Plan as detailed below.
The Options are exercisable at nil cost and are subject to continuous employment with the Company for a period of three years ending on 11 June 2026.
| Inspiration Healthcare Group plc | Tel: +44 (0)330 175 0000 |
| Neil Campbell, Chief Executive Officer | |
| | |
| Liberum (Nominated Adviser & Broker) | Tel: +44 (0)20 3100 2000 |
| Phil Walker, Richard Lindley, William Hall, Will King | |
|
| |
| Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 |
| Anna Dunphy/Stephanie Cuthbert | |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||||
| a) | Name | 1. Alan Olby | ||||||
| 2 | Reason for the notification | |||||||
| a) | Position/status | 1. PDMR (CFO) | ||||||
| b) | Initial notification /Amendment | Initial | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name | Inspiration Healthcare Group plc | ||||||
| b) | LEI | 213800GKFT3ENAPMDL15 | ||||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a)
| Description of the financial instrument, type of instrument Identification code | Options over Ordinary Shares of 10p each in the capital of the Company ISIN: GB00BXDZL105 | ||||||
| b) | Nature of the transaction | Grant of Options under the Long Term Incentive Plan | ||||||
| c)
| Price(s) and volume(s)
|
| ||||||
| d)
| Aggregated information -Aggregated volume - Price |
| ||||||
| e) | Date of the transaction | 12 June 2023 | ||||||
| f) | Place of the transaction | Outside of a trading venue | ||||||
About Inspiration Healthcare
Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in neonatal intensive care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.
The Company has key own brand products that can be used within the first days of life to help premature and sick babies; helping resuscitation and stabilisation in the first moments of life through to preventing brain damage and both invasive and non-invasive respiratory support in terms of capital equipment and disposable medical devices. Additionally, the Company has its own range of products for maintaining normothermia pre, during and post-surgery.
Since September 2019, the Company has acquired Vio Holdings a designer, manufacturer and supplier of single use respiratory products and sterile medical consumables and S.L.E., a leading designer, manufacturer and global provider of neonatal ventilation products. The Group generates approximately 58% of its revenues from export markets and more than half of its revenues come from its own-branded products.
With product availability actively promoted to over 80 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.
In the UK and Ireland, the Group has direct sales teams selling Group Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.
The Group operates from various sites in the UK for R&D, Marketing and operations with manufacturing based in Croydon (south London) and Hailsham (East Sussex). The Group's Head Office is located in Crawley, a short distance from London's Gatwick Airport.
Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.